Abstract

O3-2-2 - Efficacy and safety of nivolumab in patients with uterine cervical cancer, uterine corpus cancer, or soft-tissue sarcoma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Noriyuki Katsumata ... Hironobu Minami
Cancer science | VOL. 110
Noriyuki Katsumata, et. al.Noriyuki Katsumata ... Hironobu Minami
01 Sep 2019
Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study.
Cécile Dalban ... Brigitte Laguerre
Journal of Clinical Oncology | VOL. 40
Cécile Dalban, et. al.Cécile Dalban ... Brigitte Laguerre
20 Feb 2022
Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program
Sofie Joris ... Karin Pat
Journal of Geriatric Oncology | VOL. 11
Sofie Joris, et. al.Sofie Joris ... Karin Pat
30 Nov 2019
Efficacy and safety of nivolumab in metastatic melanoma: real-world practice
Melanie Saint-Jean ... Lucie Peuvrel
European Journal of Dermatology | VOL. 29
Melanie Saint-Jean, et. al.Melanie Saint-Jean ... Lucie Peuvrel
01 May 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
H Li ... E Song
Annals of Oncology | VOL. -
H Li, et. al.H Li ... E Song
01 May 2024
View more papers